IGF-IR antagonists as adjuvants for treatment of prostate cancer
View Patent ↗The present invention relates to a method of treating prostate cancer with androgen deprivation therapy and an insulin-like growth factor receptor (IGF-IR) antagonist. Although the response rate of prostate cancer to androgen deprivation therapy (ADT) is high, surviving cancer cells invariably become androgen independent (AI) and tumor growth follows. The invention inhibits or delays transition of androgen dependent cancer to androgen independent cancer, significantly decreases risk of recurrence, and improves treatment outcome.
1. A method of inhibiting transition of an androgen dependent cancer to an androgen independent cancer comprising administering an IGF-IR antagonist, wherein the IGF-IR antagonist is IMC-A12, and inhibiting growth of the androgen dependent cancer comprising administering androgen deprivation therapy.
2. The method of claim 1 , wherein the androgen dependent cancer is prostate cancer.
3. The method of claim 1 , wherein the androgen deprivation therapy and the IGF-IR antagonist are initiated at about the same time.
4. The method of claim 1 , wherein the IGF-IR antagonist is initiated after the androgen deprivation therapy and before the androgen dependent cancer becomes androgen independent.
5. The method of claim 1 , wherein the method of inhibiting growth of the androgen dependent cancer further comprises administering an IGF-IR antagonist.
6. The method of claim 1 , wherein the androgen deprivation therapy comprises administering a luteinizing hormone-releasing hormone (LHRH) analog.
7. The method of claim 1 , wherein the androgen deprivation therapy comprises administering anti-androgen treatment.
8. The method of claim 1 , wherein the androgen deprivation therapy comprises administering an adrenal androgen inhibitor.
9. The method of claim 1 , wherein the androgen deprivation therapy is orchiectomy.
10. The method of claim 1 , wherein the androgen deprivation therapy and the IGF-IR antagonist are administered with an anti-neoplastic agent.
11. The method of claim 10 , wherein the anti-neoplastic agent is radiation.
12. A method of inhibiting transition of an androgen dependent cancer to an androgen independent cancer comprising administering an IGF-IR antagonist, wherein the IGF-IR antagonist is IMC-A12.
13. The method of claim 12 , wherein the androgen dependent cancer is prostate cancer.